The European Medications Agency has provided protocol tips regarding the trial design within its Protocol Assistance program. ARIAD and its own partner, Merck & Co., Inc., have a worldwide collaboration to develop and commercialize ridaforolimus in oncology jointly.. ARIAD Pharmaceuticals completes enrollment of individuals for Stage 3 clinical trial of ridaforolimus ARIAD Pharmaceuticals, Inc. today announced the completion of individual enrollment in its pivotal, Phase 3 clinical trial of oral ridaforolimus, its investigational mTOR inhibitor, in individuals with metastatic soft-tissue and bone sarcomas.64-slice CT scanner most dosage efficient for evaluating pregnant sufferers with possible pulmonary emboli The 64-slice CT scanner delivers the most effective radiation dosage to pregnant patients with possible pulmonary emboli providing less risk to the fetus, according to a report performed at SUNY Stony Brook University Medical Center in Stony Brook, NY. Simulated pulmonary and pelvic studies had been performed on anthropomorphic phantoms to look for the estimated dosage range for fetal publicity using CT scanners. ‘The 64-slice is the most dose effective when the fetus is normally outside the direct scan field for pulmonary angiograms,’ stated Anthony Gilet, MD, lead writer of the scholarly study. During the first, second and third trimester the 4-slice scanner measured .082, .077 and .067 cGy; the 16-slice scanner measured .054, .025 and .084; and the 64-slice scanner measured .032, .016 and .053.